Vaccination study tool
With the Vaccination Study Tool you can easily register to participate in studies on new (corona) vaccines.
Publish date: December 2020
Commissioned by: UMC Utrecht
On the initiative of UMC Utrecht, the Vaccination Study(s) Tool has been developed. On this website anyone can register to be eligible to participate in a COVID-19 study. On December 28th 2020, the phase IIb/III study started with the COVID-19 candidate vaccine of CureVac. This study has been approved by the Central Committee on Research Involving Human Subjects (CCMO). Other Dutch hospitals have since joined in and the website is being expanded with new studies. The availability of several vaccines against corona is crucial to slow down and if possible stop the pandemic.
In addition to the primary objective of further establishing the safety of the vaccine, the study design also includes two primary efficacy objectives: (a) to demonstrate the efficacy of the vaccine in preventing first episodes of confirmed COVID-19 and (b) to prevent moderate to severe confirmed COVID-19, in participants who have never been infected with SARS-CoV-2 virus.
Anyone considering taking part in the study can register at www.vaccinatiestudie.nl. After registration, you will be contacted by phone or e-mail to discuss everything and to see if you can participate. There will also be ample opportunity to ask questions of the research team. Only when it has been established that you can participate, will you decide whether you wish to take part.